EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial

Tomohiro Fukuda iD, Yasuhiro Aoki, Hiroki Kiyohara iD, Ayumi Yokoyama, Atsushi Nakazawa, Yusuke Yoshimatsu, Shinya Sugimoto iD, Kosaku Nanki, Yohei Mikami, Kayoko Fukuhara, Shinta Mizuno, Tomohisa Sujino und 8 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae088 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Tomohiro Fukuda und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endoscopic healing is generally defined as Mayo endoscopic subscore (MES) ≤1 in ulcerative colitis (UC). However, patients with an MES of 1 are at higher relapse risk than those with an MES of 0. This study evaluated the therapeutic efficacy of proactive dose escalation of oral 5-aminosalicylic acid (5-ASA) in UC patients with an MES of 1.

Methods

An open-label, randomized controlled trial was conducted in 5 hospitals between 2018 and 2022. Ulcerative colitis patients in clinical remission under oral 5-ASA therapy and diagnosed as having an MES of 1 were enrolled. Patients receiving maintenance therapy other than 5-ASA and immunomodulator were excluded. Patients were randomly assigned in a 1:1 ratio to receive either a dose-escalated (intervention) or constant dose (control) of 5-ASA. Concomitant immunomodulator was used as the stratification factor in the randomization. The primary end point was relapse within 1 year. The subgroup analysis was stratified for the use of immunomodulators.

Results

The full analysis set included 79 patients (39 intervention and 40 control). Immunomodulators were used in 20 (25.3%) patients. Relapse was less in the intervention group (15.4%) than the control group (37.5%; P = .026). In the subgroup with concomitant immunomodulators, relapse was also less in the intervention group (10.0%) than the control group (70.0%; P = .020). In patients without immunomodulators, the difference was not significant between 2 groups (intervention, 17.2%; control, 26.7%; P = .53).

Conclusions

Dose escalation of 5-ASA reduced relapse within 1 year in UC patients in clinical remission with an MES of 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMesalamineAnti-Inflammatory Agents, Non-SteroidalHumansFemaleMaleAdultMiddle AgedAdministration, OralDose-Response Relationship, DrugRecurrenceTreatment OutcomeSeverity of Illness IndexColonoscopyRemission Induction

Stichwörter der Autor:innen

colonoscopyinflammationinflammatory bowel diseaselarge intestineulcerative colitis

Substanzen

MesalamineAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Department of Gastroenterology, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Center for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Tomohiro Fukuda, Hiroki Kiyohara, Shinya Sugimoto

Zitieren

APA

Fukuda, T., Aoki, Y., Kiyohara, H., Yokoyama, A., Nakazawa, A., Yoshimatsu, Y., Sugimoto, S., Nanki, K., Mikami, Y., Fukuhara, K., Mizuno, S., Sujino, T., Mutaguchi, M., Takabayashi, K., Morohoshi, Y., Hosoda, Y., Ogata, H., Iwao, Y., Naganuma, M., & Kanai, T. (2025). Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae088

Vancouver

Fukuda T, Aoki Y, Kiyohara H, Yokoyama A, Nakazawa A, Yoshimatsu Y, et al. Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae088

BibTeX
@article{Fukuda2025,
  author = {Fukuda, Tomohiro and Aoki, Yasuhiro and Kiyohara, Hiroki and Yokoyama, Ayumi and Nakazawa, Atsushi and Yoshimatsu, Yusuke and Sugimoto, Shinya and Nanki, Kosaku and Mikami, Yohei and Fukuhara, Kayoko and Mizuno, Shinta and Sujino, Tomohisa and Mutaguchi, Makoto and Takabayashi, Kaoru and Morohoshi, Yuichi and Hosoda, Yasuo and Ogata, Haruhiko and Iwao, Yasushi and Naganuma, Makoto and Kanai, Takanori},
  title = {Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae088}
}
Kostenlos starten →